03:53 AM EDT, 06/03/2024 (MT Newswires) -- AstraZeneca ( AZN ) said Sunday that a phase 3 trial of Enhertu showed ""statistically significant and clinically meaningful improvement" in treating certain types of metastatic breast cancer over chemotherapy.

The patients included those with HR-positive, HER2-low metastatic breast cancer as well as the overall trial population of patients with HR-positive, HER2-low and HER2-ultralow following one or more lines of endocrine therapy.

The results showed Enhertu reduced the risk of disease progression or death by 37% to 38%, the company said.

The median progression-free survival was 13.2 months in the ENHERTU arm compared to 8.1 months in the chemotherapy arm as assessed by blinded independent central review.

Enhertu, also known as fam-trastuzumab deruxtecan-nxki, is an antibody drug conjugate developed by Daiichi Sankyo. AstraZeneca ( AZN ) and the Japanese pharmaceutical firm are jointly developing and commercializing it.

Price: 77.84, Change: -0.18, Percent Change: -0.23